FDA Approves Medicines360's sNDA for LILETTA(R) (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Four Years

Approval Offers Women Additional Flexibility for Pregnancy Prevention DUBLIN AND SAN FRANCISCO, Aug. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonp... Biopharmaceuticals, Drug Delivery, FDA Allergan, Medicines360, LILETTA, levonorgestrel, intrauterine

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2042836

Source: HSMN NewsFeed - August 7, 2017 Category: Pharmaceuticals Source Type: news